The Senate today passed the FDA Reauthorization Act of 2017 (FDARA) in a roll call vote.
The Senate today passed the FDA Reauthorization Act of 2017 (FDARA) in a roll call vote.
The bill, which reauthorizes user fees for biosimilar product applications, among other provisions, will ensure funding for the continued operations of the FDA. The Senate voted on the bill following Senate Majority Leader Mitch McConnell’s (R-Kentucky) Tuesday filing of a cloture motion (limiting consideration of a pending bill to 30 additional hours) on the bill to proceed.
Despite the fact that the FDARA had broad, bipartisan support and had been passed by the House on July 13, the Senate’s consideration of the bill was delayed by contentious debate over Republican efforts at healthcare reform. The act also faced pressure from Senator Ron Johnson (R-Wisconsin), who had vowed to block the legislation’s passage unless it included an amendment comprising his “right-to-try” legislation.
However, Inside Health Policy reports that sources close to the Senate say that Johnson agreed not to hold up the timely passage of the FDARA in exchange for the swift consideration of his legislation in a separate vote. The Senate passed Johnson’s bill, the “Trickett Wendler, Frank Mongiello and Jordan McLinn Right to Try Act of 2017,” just hours before the vote on FDA reauthorization. Johnson’s sponsored legislation will allow patients who are terminally ill to access experimental treatments that are under investigation, though not yet approved, by the FDA.
While Senator Johnson eventually supported the bill, Senator Bernie Sanders (I-Vermont) cast the sole vote in opposition. Sanders, who had demanded that the FDARA include provisions for the importation of cheaper drugs from other countries, had previously voted against advancing the bill out of committee.
Now that the FDARA has passed both houses, it faces one last potential hurdle: the Trump Administration. On July 12, the White House released a statement asserting that Congress should provide for 100% of FDA program funding through user fees. While the statement indicated that the administration was in support of the goals of the act, it remains to be seen whether that support will extend to the fee structure agreed upon by Congress.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
The Subcutaneous Revolution: Zymfentra and the Future of IBD Care With Dr Andres Yarur
December 17th 2023On this episode of Not So Different, Andres Yarur, MD, a researcher and associate professor of medicine at Cedars-Sinai Medical Center, discusses the significance of the FDA approval for Zymfentra, the world's first subcutaneous infliximab product, for patients with inflammatory bowel disease (IBD).
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
Biosimilars Council: PBM Rebate Schemes Cost Americans, Payers $6 Billion
April 10th 2024A report from the Biosimilars Council evaluating IQVIA data found that rebate schemes orchestrated by pharmacy benefit managers (PBMs) are costing US patients and payers billions of dollars by suppressing biosimilar adoption.